EcoDrugPlus

Nad(P)h Dehydrogenase, Quinone 1

Ensembl ID : ENSXETG00000017869
Gene Symbol: NQO1
6 Enzyme and pathways 5 View Cross-references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nadph Oxidase 4

Ensembl ID : ENSXETG00000011734
Gene Symbol: NOX4
5 View Cross-references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSXETG00000001808
Gene Symbol: NFE2L2
9 Enzyme and pathways 5 View Cross-references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Npc1 Like 1

Ensembl ID : ENSXETG00000019001
Gene Symbol: NPC1L1
3 Enzyme and pathways 5 View Cross-references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

P2x Purinoceptor 7

Ensembl ID : ENSXETG00000045626
Gene Symbol: LOC100490828
9 Enzyme and pathways 3 View Cross-references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

P2y Purinoceptor 2

Ensembl ID : ENSXETG00000036724
Gene Symbol: LOC100489852
3 View Cross-references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

P2y Purinoceptor 2-Like

Ensembl ID : ENSXETG00000039207
Gene Symbol: LOC116406441
10 Enzyme and pathways 5 View Cross-references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSXETG00000014529
Gene Symbol: PIM3
5 View Cross-references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Putative Ortholog Of Cgmp Phosphodiesterase (Phosphodiesterase Type 9), 1 Of 1

Ensembl ID : ENSXETG00000003933
Gene Symbol: XB990243
4 Enzyme and pathways 5 View Cross-references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rar Related Orphan Receptor C

Ensembl ID : ENSXETG00000002131
Gene Symbol: RORC
4 Enzyme and pathways 5 View Cross-references
382 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSXETG00000026173
Gene Symbol: RELA
55 Enzyme and pathways 5 View Cross-references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ros Proto-Oncogene 1 , Receptor Tyrosine Kinase

Ensembl ID : ENSXETG00000037537
Gene Symbol: ROS1
5 View Cross-references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).